Bcma-Gprc5D Car-T
Multiple Myeloma Refractory
Guangzhou Bio-gene Technology Co., LtdCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 89/ 100
Competitive context
3 Active assets in the Multiple Myeloma Refractory cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Anti-Bcma Car T Cells Hebei Senlang Biotechnology Inc., Ltd. | Phase 1/2 | CCC |
hul001 HuniLife Biotechnology, Inc. | Phase 1/2 | CCC |
Liposomal Curcumin University Health Network, Toronto | Phase 1 | CC |
Same molecule, other indications
Bcma-Gprc5D Car-T is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →